• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

China Medical Technologies Participated in the 6th International Symposium on Therapeutic Ultrasounds and Presented the Pre-IDE Animal Test Results for the HIFU Therapy System

Posted on: Friday, 8 September 2006, 09:00 CDT

China Medical Technologies, Inc. (the "Company") (NASDAQ:CMED), a leading China-based medical device company that develops, manufactures and markets high intensify focused ultrasound (HIFU) products and advanced in-vitro diagnostic systems, today announced that it participated in the 6th Symposium on Therapeutic Ultrasound (ISTU6), held at the Oxford University Examination Schools between Wednesday August 30, and Saturday September 2, 2006.

The ISTU6 was organized by the International Society of Therapeutic Ultrasound, a leading association for the therapeutic ultrasound technology. The ISTU6 attracted hundreds of scientists and practitioners from all over the world. Physicians and scientists from China and the United States presented three papers on the recent development of China Medical's HIFU therapy system.

Dr. Liulin Xiong from Beijing University People's Hospital presented a clinical study reporting on 62 pancreatic cancer patients treated in China. Dr. Xiong's paper showed that the local effective control rate was 71.7% and pain palliation rate was 87% using China Medical's HIFU therapy system.

Dr. Joo Ha Hwang, on behalf of the clinical study team from the Department of Medicine of the University of Washington, presented the pre-IDE animal test results during the conference. Dr. Hwang concluded that using China Medical HIFU therapy system to treat pancreas is feasible and safe, and lesion formation of coagulative necrosis and apoptosis can be observed following proper treatment protocol. The clinical study team intends to use the animal test results to apply for the Investigational Device Exemption for FDA clinical studies.

About China Medical Technologies:

China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets products using high intensity focused ultrasound for the treatment of solid cancers and benign tumors and advanced in-vitro diagnostics products using enhanced chemiluminescence technology, to detect and monitor various diseases and disorders. For more information, please visit our website at www.chinameditech.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will,""expects,""anticipates,""future,""intends,""plans,""believes,""estimates" and similar statements. Among other things, the University of Washington's intention to use the animal test results to apply for the Investigational Device Exemption for FDA clinical studies contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in China Medical's filings with the U.S. Securities and Exchange Commission, including its registration statement on Form F-1. China Medical does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

Source: Business Wire

More News in this Category